Saulius Cicėnas

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.2K citations · Full text

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study

Federico Cappuzzo, Tudor–Eliade Ciuleanu, Lilia Stelmakh et al. · The Lancet Oncology · 2010 · 1.2K citations · Full text

Placebo-controlled Phase 3, Maintenance Treatment, Medicine +7

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study

Tudor–Eliade Ciuleanu, Lilia Stelmakh, Saulius Cicėnas et al. · The Lancet Oncology · 2012 · 371 citations

Second-line Treatment, Oncology, Cancer Management +6

SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC

Federico Cappuzzo, Tudor–Eliade Ciuleanu, L. Stelmakh et al. · Journal of Clinical Oncology · 2009 · 125 citations

Advanced Nsclc, Saturn Study, Oncology +15

Lung cancer in patients with tuberculosis

Saulius Cicėnas, Vladislavas Vencevičius · World Journal of Surgical Oncology · 2007 · 83 citations · Full text